BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34717958)

  • 1. Engineered variants of the Ras effector protein RASSF5 (NORE1A) promote anticancer activities in lung adenocarcinoma.
    Singh A; Erijman A; Noronha A; Kumar H; Peleg Y; Yarden Y; Shifman JM
    J Biol Chem; 2021 Dec; 297(6):101353. PubMed ID: 34717958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ras regulates SCF(β-TrCP) protein activity and specificity via its effector protein NORE1A.
    Schmidt ML; Donninger H; Clark GJ
    J Biol Chem; 2014 Nov; 289(45):31102-10. PubMed ID: 25217643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dynamic mechanism of RASSF5 and MST kinase activation by Ras.
    Liao TJ; Jang H; Tsai CJ; Fushman D; Nussinov R
    Phys Chem Chem Phys; 2017 Mar; 19(9):6470-6480. PubMed ID: 28197608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch II.
    Stieglitz B; Bee C; Schwarz D; Yildiz O; Moshnikova A; Khokhlatchev A; Herrmann C
    EMBO J; 2008 Jul; 27(14):1995-2005. PubMed ID: 18596699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the NORE1A tumor suppressor in Oncogene-Induced Senescence.
    Barnoud T; Schmidt ML; Donninger H; Clark GJ
    Cancer Lett; 2017 Aug; 400():30-36. PubMed ID: 28455242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The growth and tumor suppressor NORE1A is a cytoskeletal protein that suppresses growth by inhibition of the ERK pathway.
    Moshnikova A; Frye J; Shay JW; Minna JD; Khokhlatchev AV
    J Biol Chem; 2006 Mar; 281(12):8143-52. PubMed ID: 16421102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NORE1A tumor suppressor candidate modulates p21CIP1 via p53.
    Calvisi DF; Donninger H; Vos MD; Birrer MJ; Gordon L; Leaner V; Clark GJ
    Cancer Res; 2009 Jun; 69(11):4629-37. PubMed ID: 19435914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nore1 and RASSF1 regulation of cell proliferation and of the MST1/2 kinases.
    Avruch J; Praskova M; Ortiz-Vega S; Liu M; Zhang XF
    Methods Enzymol; 2006; 407():290-310. PubMed ID: 16757333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth and tumor suppressor NORE1A is a regulatory node between Ras signaling and microtubule nucleation.
    Bee C; Moshnikova A; Mellor CD; Molloy JE; Koryakina Y; Stieglitz B; Khokhlatchev A; Herrmann C
    J Biol Chem; 2010 May; 285(21):16258-66. PubMed ID: 20339001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells.
    Wang Y; Godin-Heymann N; Dan Wang X; Bergamaschi D; Llanos S; Lu X
    Cell Death Differ; 2013 Apr; 20(4):525-34. PubMed ID: 23392125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ras Regulates Rb via NORE1A.
    Barnoud T; Donninger H; Clark GJ
    J Biol Chem; 2016 Feb; 291(6):3114-23. PubMed ID: 26677227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NORE1A is a double barreled Ras senescence effector that activates p53 and Rb.
    Donninger H; Barnoud T; Clark GJ
    Cell Cycle; 2016 Sep; 15(17):2263-4. PubMed ID: 26919075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The E3 ubiquitin ligase Itch regulates tumor suppressor protein RASSF5/NORE1 stability in an acetylation-dependent manner.
    Suryaraja R; Anitha M; Anbarasu K; Kumari G; Mahalingam S
    Cell Death Dis; 2013 Mar; 4(3):e565. PubMed ID: 23538446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformation-specific inhibitors of activated Ras GTPases reveal limited Ras dependency of patient-derived cancer organoids.
    Wiechmann S; Maisonneuve P; Grebbin BM; Hoffmeister M; Kaulich M; Clevers H; Rajalingam K; Kurinov I; Farin HF; Sicheri F; Ernst A
    J Biol Chem; 2020 Apr; 295(14):4526-4540. PubMed ID: 32086379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor suppressor ras association domain family 5 (RASSF5/NORE1) mediates death receptor ligand-induced apoptosis.
    Park J; Kang SI; Lee SY; Zhang XF; Kim MS; Beers LF; Lim DS; Avruch J; Kim HS; Lee SB
    J Biol Chem; 2010 Nov; 285(45):35029-38. PubMed ID: 20810663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive analysis of RAS-effector interactions reveals interaction hotspots and new binding partners.
    Rezaei Adariani S; Kazemein Jasemi NS; Bazgir F; Wittich C; Amin E; Seidel CAM; Dvorsky R; Ahmadian MR
    J Biol Chem; 2021; 296():100626. PubMed ID: 33930461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ras signaling through RASSF proteins.
    Donninger H; Schmidt ML; Mezzanotte J; Barnoud T; Clark GJ
    Semin Cell Dev Biol; 2016 Oct; 58():86-95. PubMed ID: 27288568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and Characterization of Oncogenic
    Cai D; Choi PS; Gelbard M; Meyerson M
    Mol Cancer Res; 2019 Apr; 17(4):1002-1012. PubMed ID: 30635434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Ras with protein engineering.
    Tomazini A; Shifman JM
    Oncotarget; 2023 Jul; 14():672-687. PubMed ID: 37395750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases.
    Aoyama Y; Avruch J; Zhang XF
    Oncogene; 2004 Apr; 23(19):3426-33. PubMed ID: 15007383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.